To investigate the frequency and the biology of the metabolic syndrome in childhood cancer survivors in order to find risk factors for cerebro- and cardiovascular diseases and to design preventive intervention strategies in indicated risk groups
ID
Source
Brief title
Condition
- Glucose metabolism disorders (incl diabetes mellitus)
- Lipid metabolism disorders
- Arteriosclerosis, stenosis, vascular insufficiency and necrosis
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
- blood pressure
- body composition
- (abdominal) obesity
- glucose metabolism
- lipidspectrum
Secondary outcome
-polymorphisms
-other parameters associated with the metabolic syndrome:
*biomarkers for endothelial function
*pro-inflammatory markers
*pro-thrombotic factors
*biomarkers for adiposity
*urine-analysis
- results of fitness test
Background summary
As currently the majority of children with cancer survives, the absolute number
of adult survivors is increasing. Therefore, long-term toxicity issues become
increasingly important. In the general population the metabolic syndrome has
become one of the major public health challenges worldwide as it identifies
individuals at risk of both type 2 diabetes and cerebro- and cardiovascular
disease. It is conceivable that adults who survived childhood cancer may be at
risk for developing metabolic syndrome due to treatment related factors.
Study objective
To investigate the frequency and the biology of the metabolic syndrome in
childhood cancer survivors in order to find risk factors for cerebro- and
cardiovascular diseases and to design preventive intervention strategies in
indicated risk groups
Study design
This will be a prospective cohort study.
The determinants of the metabolic syndrome will be investigated in a group of
600 childhood cancer survivors who have been treated in the ErasmusMC-Sophia
Children's Hospital.
As the prevalence of these determinants is also increasing in the normal
population, it is very important to investigate these determinants also in a
group of healthy controlpersons, to be able to compare the survivors with he
normal population.
Study burden and risks
Participation in this research will require approximately one day, with a
maximum of 1 day and a few hours on a second day.
The risk of the imaging studies and the vena punction is minimal.
Dr. Molewaterplein 60
3015 GJ Rotterdam
NL
Dr. Molewaterplein 60
3015 GJ Rotterdam
NL
Listed location countries
Age
Inclusion criteria
Patient:
- history of childhood cancer
- treated in ErasmusMC-Sophia
- at least 18 years old
- minimum of 5 years after cessation of therapy
Control:
- preferrably brother or sister of the patient, if not available;
- friend or neighbour of survivor of same sex and approximately same age, within a range of 5 years.
Exclusion criteria
Patient:
- when partly treated in other country
Controls:
- when they also have a history of childhood cancer
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL26325.078.08 |